Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial - Vansteenkiste, Johan F.; Hoffmann, Hans (The lancet. Oncology, 2016)
Gesehen am 15.08.2019